It is possible that the lower frequency of DNMT3A mutations in our study could be associated: 1) to the lower frequency of patients with MDS-RS in whom DNMT3A mutations frequently associate with SF3B1 mutations(7) and 2) to the overall smaller patient cohort and the lower median age of included patients (66 years compared to 68 years in the study by Papaemmanuil et al and 72.5 years in the study by Haferlach et al) as, mutations in DNMT3A, are typical of age-related clonal hematopoiesis and could be more prevalent in older individuals. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.